Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ · Healthcare
Ultragenyx Pharmaceutical Inc. Shareholder Equity 2016–2025
Ultragenyx Pharmaceutical Inc. annual shareholder equity history from 2016 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Ultragenyx Pharmaceutical Inc. shareholder equity as of December 31, 2025: -80.0M, a 131.37% decrease year-over-year.
- Ultragenyx Pharmaceutical Inc. shareholder equity for 2025 were -80.0M, a 131.37% decrease from 2024.
- Ultragenyx Pharmaceutical Inc. shareholder equity for 2024 were 255.0M, a 7.27% decrease from 2023.
- Ultragenyx Pharmaceutical Inc. shareholder equity for 2023 were 275.0M, a 21.88% decrease from 2022.
- Ultragenyx Pharmaceutical Inc. shareholder equity for 2022 were 352.0M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Ultragenyx Pharmaceutical Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $-80 |
| 2024 | $255 |
| 2023 | $275 |
| 2022 | $352 |
| 2021 | $923 |
| 2020 | $1,154 |
| 2019 | $654 |
| 2018 | $609 |
| 2017 | $383 |
| 2016 | $474 |
Ultragenyx Pharmaceutical Inc. Shareholder Equity — FAQ
Ultragenyx Pharmaceutical Inc. (RARE) shareholder equity over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see RARE's shareholder equity history?
The chart and table above show Ultragenyx Pharmaceutical Inc.'s shareholder equity by year and by quarter, including the growth rate.